How COVID-19 has fundamentally changed clinical research in global health by Park, Jay J H et al.
eCommons@AKU 
Department of Paediatrics and Child Health Division of Woman and Child Health 
5-1-2021 
How COVID-19 has fundamentally changed clinical research in 
global health 
Jay J H. Park 
Robin Mogg 
Gerald E. Smith 
Etheldreda Nakimuli-Mpungu 
Fyezah Jehan 
See next page for additional authors 
Follow this and additional works at: https://ecommons.aku.edu/
pakistan_fhs_mc_women_childhealth_paediatr 
 Part of the Maternal and Child Health Commons, Pediatrics Commons, and the Virus Diseases 
Commons 
Authors 
Jay J H. Park, Robin Mogg, Gerald E. Smith, Etheldreda Nakimuli-Mpungu, Fyezah Jehan, Craig R. Rayner, 
Jeanine Condo, Eric H. Decloedt, Jean B. Nachega, Gilmar Reis, and Edward J. Mills 
www.thelancet.com/lancetgh   Vol 9   May 2021 e711
Series
Lancet Glob Health 2021; 
9: e711–20
See Comment page e575
This is the fourth in a Series of 
four papers about clinical trials in 
global health




Department of Experimental 
Medicine, University of British 
Columbia, Vancouver, BC, 
Canada (J J H Park MSc); 
Bill & Melinda Gates Medical 
Research Institute, Boston, 
MA, USA (R Mogg PhD); 
Department of Health 
Research Methods, Evidence, 
and Impact, McMaster 
University, Hamilton, ON, 
Canada (G E Smith MSc, 
Prof E J Mills FRCP); Cytel, 
Vancouver, BC, Canada 
(Prof E J Mills); Department of 
Psychiatry, Makerere 
University, Kampala, Uganda 
(E Nakimuli-Mpungu PhD); 
Department of Pediatrics and 
Child Health, Aga Khan 
University, Karachi, Pakistan 
Clinical Trials in Global Health 4
How COVID-19 has fundamentally changed clinical research 
in global health
Jay J H Park, Robin Mogg, Gerald E Smith, Etheldreda Nakimuli-Mpungu, Fyezah Jehan, Craig R Rayner, Jeanine Condo, Eric H Decloedt, 
Jean B Nachega, Gilmar Reis, Edward J Mills
COVID-19 has had negative repercussions on the entire global population. Despite there being a common goal that 
should have unified resources and efforts, there have been an overwhelmingly large number of clinical trials that have 
been registered that are of questionable methodological quality. As the final paper of this Series, we discuss how the 
medical research community has responded to COVID-19. We recognise the incredible pressure that this pandemic has 
put on researchers, regulators, and policy makers, all of whom were doing their best to move quickly but safely in a time 
of tremendous uncertainty. However, the research community’s response to the COVID-19 pandemic has prominently 
highlighted many fundamental issues that exist in clinical trial research under the current system and its incentive 
structures. The COVID-19 pandemic has not only re-emphasised the importance of well designed randomised clinical 
trials but also highlighted the need for large-scale clinical trials structured according to a master protocol in a coordinated 
and collaborative manner. There is also a need for structures and incentives to enable faster data sharing of anonymised 
datasets, and a need to provide similar opportunities to those in high-income countries for clinical trial research in low-
resource regions where clinical trial research receives considerably less research funding.
Introduction 
Since the beginning of this Series on clinical trials in 
global health, the global pandemic of COVID-19 has 
occurred. This major global health threat has highlighted 
the importance of global health by reminding us how 
diseases arising from a single country can affect all other 
countries, and how health risks and inequities transcend 
national borders. The pandemic has had negative ramifi-
cations on the entire global population. We recognise the 
incredible pressure this pandemic has put on researchers, 
regulators, and policy makers, all of whom are doing their 
best to move quickly but safely in a time of tremendous 
uncertainty, but the readiness of the research community 
to bring about rapidly informed decisions on the basis of 
research evidence has been inadequate. The challenges 
faced in the global response to initiate and coordinate 
COVID-19 clinical trials are not new, but the problems 
and limitations that have existed for clinical trial research 
have arguably become much more visible.
Despite there being a common goal that should unify 
resources and efforts, clinical research efforts around the 
world might easily be described as chaotic and exclusive 
of many low-income and middle-income countries 
(LMICs). The global collective clinical trial response to 
COVID-19 has occurred with inadequate collaboration 
between researchers. Inconclusive research findings 
from many clinical trials have re-emphasised the 
importance of high-quality clinical trial research.
As the final paper of this Series on global health trial 
research, we discuss the need to embrace coordination 
and collaboration instead of competition in medical and 
public health research. We specifically draw on the 
COVID-19 pandemic to describe how the research 
community has responded to the outbreak.
How the medical research community has 
responded to COVID-19
The new norm of publishing: quantity over quality
The COVID-19 pandemic’s threat to global security and 
the economy has captured the entire world’s attention. 
The number of COVID-19 cases continues to rise globally 
with little sign of slowing down.1 The COVID-19 
pandemic has mobilised researchers worldwide on a 
scale and timeframe that have never been seen before for 
one specific disease. In hopes of rapid discovery of 
therapeutics, vaccines, and diagnostics for COVID-19, a 
substantial amount of money is being invested towards 
clinical research. Despite the sheer volume of research 
Key messages
• The incredible pressure that the COVID-19 pandemic has put on researchers, regulators, 
and policy makers, all of whom were doing their best to move quickly but safely in a 
time of tremendous uncertainty, should be recognised. However, the medical research 
community’s response to COVID-19 has arguably been inefficient and wasteful, with an 
overwhelmingly large number of clinical trials having been registered and done with 
questionable methodological quality. The COVID-19 pandemic has highlighted the 
need for more coordination and collaboration in clinical trial research.
• Most clinical trials that have been done for COVID-19 have been too small in scale to 
provide conclusive evidence. Investing in large-scale clinical trials that can facilitate 
international collaboration will be important to generate high-quality data efficiently 
that can inform policy and change clinical and public health practices.
• Instead of independent clinical trials, coordination and collaboration could be more 
effectively facilitated by consolidating funds towards master protocols.
• Although sharing of individual participant-level data has historically proven to be 
challenging from both private and public researchers, as shown by the COVID-19 
pandemic, there is a need to mandate data sharing, expedite systems to apportion 
credit for data sharing, and preserve commercial interests.
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and discussion on the research related to COVID-19, we 
will illustrate in this Series paper that we are not fighting 
this common fight very efficiently.
In response to COVID-19, the research community 
has rapidly adopted a new way of research dissemination 
but, unfortunately, how that research is being done has 
not changed. There has been a surge of COVID-19-related 
preprints and peer-reviewed publi cations on a scale 
that has never been seen in other areas of health-
care research.2–4 As of Sept 30, 2020, there were 
9214 COVID-19-related preprints on major preprint 
servers such as medRxiv and bioRxiv.5 The number of 
COVID-19 manuscripts being submitted for peer review 
has also greatly increased. For instance, The Journal of the 
American Medical Association has indicated that more 
than 11 000 manuscripts were submitted between Jan 1 
and June 1, 2020, whereas around 4000 manuscripts 
were submitted during the same period in 2019.4 
Scientific journals have accelerated their peer review 
process to expedite the publications of studies for 
COVID-19·2,4,6 One analysis shows that the time between 
submission and publication of articles on COVID-19 has 
decreased on average by around 50%, from 117 days 
down to 60.6 This analysis also showed that the time to 
publication for research not related to COVID-19 has 
remained unaffected,6 but it is probable that the number 
of research articles unrelated to COVID-19 has dropped 
considerably, with COVID-19 predominating in receipt of 
funding and attention from the research community.
There are clear merits of preprint servers and having a 
faster peer review process, as results can be disseminated 
quicker and potentially be used to inform policies and 
speed up the research and development (R&D) process 
for COVID-19 therapeutics and vaccines. Unfortunately, 
COVID-19 research has largely not been of high quality 
so far and many preprints, which are not peer-reviewed, 
were rushed to dissemination without sufficient 
oversight. The differentiation between preprints and 
peer-reviewed publications with appropriate oversight 
became blurred. The floods of preprints and publications 
from COVID-19 research have created confusion, not 
only among the scientific community, but also among 
the public, who are eagerly waiting for the scientific 
community to make the next breakthrough for 
COVID-19. The aim is to strike a balance between 
quickly disseminating data via preprint servers while 
ensuring that the work is scientifically credible.
The clinical trial landscape for COVID-19
During the COVID-19 pandemic, the importance of 
well designed randomised clinical trials has been re-
emphasised,7,8 owing to studies being published with 
questionable findings9–12 and due to an overwhelming 
number of COVID-19 clinical trials that are being done 
without methodological rigour and adequate planning.13 
Close to 2516 clinical trials were registered globally as of 
Nov 27, 2020 with 1278 actively recruiting partici pants.13 
These trials are looking at patients in contexts ranging 
from pre-exposure prophy laxis through to severely ill 
hospitalised patients. The experimental interventions 
that are being evaluated vary greatly, ranging from 
herbal preparations through to invasive medical 
procedures, vaccines, and experimental stem-cell 
therapy. The majority of trials have involved patients 
who have been admitted to hospital, and few clinical 
trials have investigated earlier stages of the disease 
process such as pre-exposure, or post-exposure and 
outpatient treatment.14 With regard to treatments, 
although there are more than 100 unique therapeutic 
agents being investigated, there is also substantial 
overlap and duplicated trial efforts as the majority of 
these trials are evaluating drugs that are already 
approved for other indications, such as hydroxy-
chloroquine and lopinavir–ritonavir, but that are being 
repurposed for COVID-19.13 These trials have, on 
average, planned sample sizes of fewer than 
100 participants, and are typically evaluating only one 
experimental intervention.13
It is also striking that study dose regimen comparisons 
have largely been absent in the current trial landscape 
of COVID-19·15 It is generally well accepted that 
confirming dose–response in a clinical environment is 
the foundation to defining an optimal dose regimen, the 
core clinical pharmacology principle that researchers 
are overlooking due to the urgency to find COVID-19 
treatments. Failing to explore an adequate dose range or 
not including dosing that accounts for pharmacokinetic 
and pharmacodynamic variability in different patient 
populations can lead to an effective treatment being 
determined as falsely ineffective.16 In addition to the 
requirements of determining a safe and effective dose, 
the shortage of clinical pharmacology in these clinical 
trials will potentially be problematic for manufacturing 
and scale-up efforts.17 As a result, clinical pharmacology 
professional societies have issued global calls to action 
to accelerate the development of COVID-19 therapeutics, 
as the ignorance relating to the science of dosing has 
added to the inefficiencies of the global clinical trial 
landscape.15
The current trial landscape of COVID-19 highlights 
important issues that illustrate the inefficiencies of 
clinical trial research. Most COVID-19 trials are small, 
so they will not provide sufficient statistical power to 
detect a meaningful treatment effect. Most will never 
achieve their target recruitment numbers. Many are 
investigating identical or similar treatments with dose 
regimen selection being made without adequate clinical 
pharmacology. The preponderance of two-arm trials 
also leads to other important issues. Instead of doing 
multi-arm or platform trials with a common control 
group, the prevalence of two-arm trials has resulted in 
multiple redundant control groups, which is an another 
example of inefficient clinical trial practices. Different 
trials being run in the same region or institution 
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will ultimately compete for participants and delay 
recruitment into well designed trials that can provide 
reliable scientific evidence.8 Given that many COVID-19 
trials have been done across different geographical 
settings without standardised operating procedures and 
have been powered according to different endpoints, it 
has been difficult to make sense of the data from these 
trials.
Problems with published peer-reviewed trials 
68 published peer-reviewed articles of randomised clinical 
trials on COVID-19 were available as of Dec 4, 2020 
(appendix pp 2–4). Given the location of where the 
COVID-19 pandemic originated, a large proportion of this 
trial evidence (21 [31%] of the 68 clinical trials) comes 
from China. Most of these clinical trials have been done 
in the hospital setting (61 [90%] of 68). Hydroxychloro-
quine was the most commonly investigated intervention 
(14 [21%])18–32 followed by lopinavir–ritonavir as either 
monotherapy33,34 or combination therapy35–37 (five [7%]), 
and remdesivir38–41 (four [6%]).
14 (21%) trials did not report any information on 
sample size or power calculation.19,42–54 The other trials 
that reported the sample size calculation had a median 
recruitment target of 186 (IQR 81·5–393) participants, 
highlighting that most of the trials were not large enough 
to provide convincing answers unless the treatment 
effect was overwhelmingly large. It is important to note 
that most of these COVID-19 trials were published 
without meeting their recruitment target due to the 
waning of the virus epidemiology in the studied regions. 
The median number of participants recruited into these 
published COVID-19 trials (87 [IQR 52–199]) was smaller 
than the median planned recruitment target. Of the 
54 trials that reported information on planned sample 
size, 25 (46%) did not meet their recruitment target; in 
fact, on average they only recruited about half of their 
planned sample (median 52·3% [IQR 31·7–80·6%]).
Despite registered trials from 40 different countries 
worldwide, the epidemiology will vary across regions due 
to differences in physical distancing and other public 
health measures. We predict that a large number of 
COVID-19 trials will stop early, not for statistical reasons 
but because of insufficient recruiment.13 For instance, 
despite the public health measures in China that reduced 
the number of active COVID-19 cases considerably, the 
number of clinical trials being registered in China, like 
many other countries around the world, has continued to 
rise.13 Given that the recruitment target greatly exceeds 
the number of daily active cases in China, the fierce 
competition for patients has led to early termination of 
many of these trials in China. While the number of 
COVID-19 cases continues to rise globally, there is likely 
to be similar competition for patients between different 
trials being done in other regions of the world.
Trials stopped early for feasibility are always going to be 
underpowered and thereby prone to produce inconclusive 
findings. Most of the COVID-19 trials will be 
underpowered, either by design or because they are 
terminated before reaching their recruitment target. 
During non-pandemic settings, the standard solution to 
the challenge of underpowered studies is to pool the 
reported aggregated results using pairwise or network 
meta-analyses.55,56 For COVID-19, there will be many 
challenges of doing meta-analyses with aggregated 
reported data. First, even within trials studying the same 
intervention, there is substantial hetero geneity in dose, 
duration, endpoints, and data collected between different 
trials. Second, there is, in general, a shortage of data 
sharing and no coordinated global approach to aggregate 
data. Lastly, trials that fail to reach their recruitment 
target are less likely to be published and thus not available 
for typical meta-analyses.
Integration of different trial datasets for individual 
participant-level data (IPD) meta-analyses might be the 
only solution in determining what works and is safe 
for COVID-19·57 However, the inadequate number of 
data sharing mechanisms that exists for COVID-19 is 
a major obstacle. For instance, except for the the USA 
and Canada randomised clinical trial on post-exposure 
hydroxychloroquine,23 the authors of other publications 
have either declined to share IPD or have indicated that 
the corresponding author can be contacted for data access 
(appendix pp 5–6). The process of obtaining de-identified 
IPD from corresponding authors is very inefficient 
and time consuming, and often does not result in data 
sharing.58 Researchers who have attempted to acquire 
IPD from other published trials know too well that a 
statement indicating that data can be accessed on request 
by contacting the corresponding authors is often just 
a requirement of the publishing process that is not 
subsequently honoured.
The need for coordination and collaboration
The research community’s fulfilment to study 
participants
When individuals participate in clinical trials, they 
often hope to gain some benefits from new treatment 
interventions, but they can end up exposing themselves 
to risks.59 Given the experimental nature of clinical 
research, risks to participants could be unavoidable. 
Although the value of clinical trials for society is differ-
ent from the benefits that clinical trial interventions 
have on  individual participants, study participants 
expect and want their data to be used responsibly to 
advance science.60 The advancement of science and 
improved public health outcomes require collaboration, 
which includes publishing of all data, regardless of the 
results, and releasing them to the research community.
A single data repository 
Sharing of IPD has historically proven to be challenging.58 
Rather than data sharing being optional, for investigators 
of COVID-19 there is a need to mandate data sharing, 
See Online for appendix
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expedite systems to apportion credit for data sharing, and 
preserve commercial interests. In the current COVID-19 
pandemic, the need to share and collaborate openly 
supersedes personal careers or organisational goals. 
Funders could facilitate data sharing by having a mandate 
of sharing anonymised data as a requirement for funding. 
Funders should also ensure that any publications resulting 
from secondary data analysis credit the data generators.
As the processes for dealing with personal privacy, 
data security, and data standardisation have become 
sufficiently more sophisticated over the past 10 years, 
there is no real barrier to centralising and sharing IPD 
from different clinical trials under one repository.61 
Investigators that have started clinical trials can utilise 
existing global clinical research data-sharing platforms, 
such as Vivli61 and Health Data Research UK, in which 
data can be collectively and securely curated and analysed. 
The data from different trials can be pooled to answer 
meaningful public health questions, rather than staying 
inconclusive in isolation.57
The need for rapid and robust clinical research for 
discovery of effective and safe therapeutics and vaccines 
has never been higher. Strengthening the public health 
response to COVID-19 will require larger collated IPD 
sets to facilitate the scientific precision required for 
accurate assessment of COVID-19 medical interventions. 
As COVID-19 has forced reconsideration of policies, 
processes, and interests, now is the time to advance 
scientific cooperation and shift the clinical research 
enterprise toward a data-sharing norm that can maximise 
the response to the COVID-19 pandemic in the service of 
public health. Given their small-scale design and inability 
to reach their recruitment target, most clinical trials done 
so far will not provide conclusive answers that can be 
used to inform new practices for COVID-19. If 
investigators of clinical trials all over the world share their 
data in a single data repository that is accessible to the 
research community, these data can be used collectively 
to make sense of which therapies work and are safe for 
patients with COVID-19. Key principles of data sharing 
are provided in panel 1.
Smarter investments for clinical trial research 
The aim of clinical trial research is to generate 
high-quality evidence to inform new clinical practices 
and public health policies. Given the scarcity of funding, 
funding clinical trial research can mean that there is less 
funding available to implement public health initiatives 
(and vice versa). Recognising this trade-off between 
clinical trial research and clinical practice and public 
health,62 investments should be made that enable 
coordination and collaboration in clinical trial research. 
Smarter investments for clinical trial research—whereby 
funds are allocated to clinical trials that are asking 
important research questions and that are well 
designed—should be made so that the funded trials have 
a high probability of generating conclusive evidence that 
can inform clinical practice and public health policies. 
As currently experienced in the era of COVID-19, 
uncoordinated funding schemes will probably continue 
funding multiple independent trials that are too small to 
provide conclusive evidence.13
The COVID-19 pandemic has catalysed the acceptance 
of master protocols by the research community as there 
is a clear need for more structured and sustainable 
approaches to clinical trial evaluation (a detailed 
discussion of master protocol framework can be found in 
the second paper of this Series63). For instance, on 
Feb 18, 2020, WHO’s R&D Blueprint—a global strategy 
and preparedness plan to increase the R&D processes 
of diagnostics, therapeutics, and vaccines during 
epidemics—released a core master protocol for 
COVID-19.64–66 This core protocol outlined plans for 
clinical trial evaluation in hospitalised patients, including 
an ordinal clinical progression scale that was formulated 
by a special WHO committee.66,67 WHO’s core master 
protocol has been widely shared as a template for 
potential COVID-19 treatments across multiple sponsors 
and investigational teams and has helped to standardise 
clinical outcomes across different trials.68
Recognising the critical importance of discovering 
effective and safe interventions for COVID-19, WHO has 
also leveraged its international influence and is doing 
an adaptive platform trial called the Solidarity trial 
(panel 2). WHO’s Solidarity I trial (ISRCTN83971151) 
has now been expanded to more than 100 countries 
worldwide since being announced on March 18, 2020, 
and is recruiting patients hospitalised with COVID-19.69 
In parallel with this trial, WHO will begin Solidarity II, a 
global serological study to better understand immunology 
Panel 1: Principles of data sharing
Data sharing in the context of clinical research can often be challenging. Researchers work 
in a global context and with a variety of internal and external tools for tracking clinical 
trial data. In tandem, legislation surrounding the transmission of personal or even 
anonymised health data varies worldwide and is subject to substantial scrutiny. Several 
international partners have worked through these hurdles and have developed key 
principles of data sharing, often referred to as the findable, accessible, interoperable, 
and reusable (FAIR) data principles. Findable data refers to developing a common system 
to allow for machine and human readable data with explicit and rich data identifiers to 
facilitate cross-collaboration. In the context of COVID-19 trials, an example could be 
unique patient identification numbers to ensure no inappropriate double-counting of 
data. Accessible data refers to the methods utilised to access and authenticate data, using 
a common protocol and facilitating security requirements for human data. In the context 
of COVID-19 trials, this method could be a validation process for researchers to access the 
shared data asset while ensuring appropriate clinical governance. Interoperable refers to 
the use of common language (ontology) to facilitate similar data standards. In the 
context of COVID-19 trials, this approach might involve harmonisation of key clinical 
characteristics (eg, disease severity) to enable appropriate selection of relevant data. 
Reusable refers to the end result of the FAIR principles, by creating a dataset that can be 
mined globally to ensure that relevant research might perpetuate through novel research 
questions and analytical capabilities, while retaining strong scientific rigour.
For more on Health Data 
Research UK see 
www.hdruk.ac.uk
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and other biological profiles of COVID-19.75 WHO is also 
planning a prophylaxis study (Solidarity III) to evaluate 
possible therapeutic options that can prevent health-care 
workers and other high-risk populations from contracting 
SARS-CoV-2.76
The international collaboration for the Solidarity trials 
is being coordinated by WHO. To facilitate collaboration 
across different hospitals and different countries, WHO 
has streamlined the patient enrolment and centralised 
web-based randomisation procedures that do not require 
paperwork. Participating countries or groups of hospitals 
are not required to participate in serial virology or other 
serial documentations of disease status to ensure that the 
burden of research duties in participating hospitals is 
minimised. In addition to a centralised randomisation 
and data capture system, harmonised statistical support 
is being provided with interim analyses being monitored 
by a global data and safety monitoring committee under 
a core master protocol. WHO has also set up a COVID-19 
Solidarity Response Fund to allow donations that will 
help fund the Solidarity trials.
Although misunderstanding of platform trials and 
master protocols is common,77–79 integrated research 
efforts for trials of COVID-19 interventions and ideally for 
other areas of research should be structured through 
master protocols and platform trials. Platform trials are 
multi-arm perpetual clinical trials that allow comparison 
between all active drugs and, on the basis of interim 
evaluations, allow arms to be dropped or added mid-trial 
to improve efficiency.77,79–81 A master protocol generally 
refers to a single overarching protocol designed to answer 
multiple interventional questions that would otherwise 
require several separate clinical trials.79,82 Under the 
master protocol framework, platform trials (and other 
innovative clinical trials) often establish a large trial 
network with a common infrastructure across and within 
multiple institutions that are able to join and leave over 
time.79–81 Between these institutions, common screening 
mechanisms, data collection, and other standardised 
operating procedures are implemented, creating a 
research ecosystem that can generate high-quality data 
and answer multiple research questions.79,80
The research ecosystem for preparedness and 
sustainability 
Important lessons from COVID-19 have illustrated the 
need for pre-existing resource-efficient trial sites and 
capacity. Efficient clinical trial research requires trained 
personnel and strong clinical and laboratory infra-
structure, data management systems, safety monitoring, 
and institutional oversight. Establishing a master 
protocol for a platform trial can help establish an 
efficient research ecosystem that is prepared for a future 
pandemic. For instance, before the COVID-19 pandemic 
occurred, a platform trial had already been prepared 
for a respiratory disease pandemic. The Randomised, 
Panel 2: WHO’s Solidarity I trial
The Solidarity I trial (ISRCTN83971151) is a multinational 
randomised clinical trial, co-sponsored by WHO and 
participating countries.69 The Solidarity I trial enrols hospitalised 
adults (aged ≥18 years) with confirmed COVID-19 to compare 
four treatment options against standard of care to assess their 
relative effectiveness against COVID-19. Study drugs include 
remdesivir, hydroxychloroquine, lopinavir (fixed-dose 
combination with ritonavir), and interferon-β1a (mainly 
subcutaneous; initially with lopinavir). Although 
hydroxychloroquine was originally one of these four treatment 
options, on June 17, 2020, WHO announced that the 
hydroxychloroquine arm would be dropped. The Executive 
Group of the Solidarity trial and principal investigators based 
this decision on evidence from the Solidarity I trial, the UK’s 
RECOVERY trial, and a Cochrane review.70–72 WHO states that the 
evidence showed that treatment with hydroxychloroquine does 
not reduce mortality in patients with COVID-19 who have been 
hospitalised compared with standard of care.69 However, the 
decision applied only to the Solidarity trial and not to studies 
evaluating hydroxychloroquine as a pre-exposure or post-
exposure prophylaxis. Under the adopted master protocol 
framework outlined in WHO’s R&D Blueprint,64,73 adults with 
COVID-19 being admitted to participating hospitals are being 
managed in a standardised way across multiple different 
institutions. The local medical team is responsible for 
identifying any unsuitable study treatments for the consenting 
patients. Following this initial assessment, identifying details 
and conditions are digitally recorded, and the patient is 
randomly allocated to one of the treatment options in a 
common electronic data capture system. Anonymised 
information is collected at randomisation and at discharge or 
death for each patient, including: study drugs and dose; use and 
duration of ventilation or intensive care; and date of discharge 
or date and cause of death in hospital. A global data and safety 
monitoring committee are monitoring the safety and interim 
efficacy of the individual interventions. More than 
12 000 patients had been recruited in 43 countries as of 
Oct 2, 2020, and more than 116 countries have expressed 
interest or joined the trial. WHO actively supports these 
countries with regard to the “ethical and regulatory approvals 
of the WHO core protocol; identification of hospitals 
participating in the trial; training of hospital clinicians on the 
web-based randomization and data system; and shipping the 
trial drugs as requested by each participating country”.74 WHO 
states that the Solidarity trial will reduce the time taken to 
design and complete randomised clinical trials by 80%. By 
recognising the importance of master protocols, this enables 
global comparisons to generate evidence to determine the 
relative effectiveness of treatments.
For more on the WHO COVID-19 
Solidarity Response Fund see 
https://covid19responsefund.
org/en/
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Embedded, Multi factorial Adaptive Platform Trial 
for Community-Acquired Pneumonia (REMAP-CAP; 
NCT02735707) is a platform trial that commenced on 
April 11, 2016.83 REMAP-CAP was already enrolling 
patients being admitted to the intensive care unit (ICU) 
for community-acquired pneumonia and had a pre-
written appendix as part of their master protocol for 
inclusion of an influenza-like population should a 
pandemic occur83 (panel 3). Other trial sites have joined 
the REMAP-CAP for the COVID-19 outbreak, expanding 
its already large research ecosystem network to 
233 active sites, and have randomised more than 
600 patients admitted to the ICU with suspected or 
proven COVID-19.
This foresight could represent an approach that 
funders and future trialists should consider by having a 
worst-case scenario in their planned master protocols. 
Strengthening the research ecosystem so that it is more 
resilient and dynamic will not only be important for the 
COVID-19 pandemic, but also for future pandemics 
and other diseases with high unmet needs that are 
difficult to treat. Master protocols can be leveraged to 
encourage collaborations to generate scientific evidence 
in a timely manner while promoting rigorous standards 
between different regions of the world. As seen with 
REMAP-CAP, the existing infrastructure established 
through the master protocol can also be leveraged and 
extended to other research questions, including critical 
questions regarding unanticipated pandemics (panel 3). 
Undoubtedly, developing a master protocol for all 
diseases and establishing clinical research networks will 
have its challenges, and will require foresight and a 
considerable amount of up-front work. But this model 
of research—large scale, collaborative, across borders, 
and designed to efficiently answer questions with 
patient-centred endpoints—will be essential for any 
new or re-emerging infectious disease outbreak.
National-level collaboration 
National-level collaboration and buy-in from major 
stakeholders are important components of clinical trial 
research, which has been exemplified by the Random ised 
Evaluation of COVID-19 Therapy (RECOVERY; 
ISRCTN50189673; NCT04381936) trial during the 
COVID-19 pandemic (panel 4). The RECOVERY trial is a 
large adaptive platform trial evaluating multiple different 
interventions for patients hospitalised with COVID-19 
across 176 hospitals in the UK. The national-level buy-in 
is highlighted in the joint letter written by the UK’s four 
medical officers and the medical director for National 
Health Service (NHS) England and NHS Improvement 
on May 6, 2020, that encouraged physicians and hospitals 
to enrol patients into the RECOVERY trial and three other 
platform trials (ie, ACCORD, PRINCIPLE, and REMAP-
CAP).86 With such national buy-in and cooperation, this 
trial was able to rapidly recruit 11 841 patients in a short 
span of around 4 months (from March 19 to June 25, 2020), 
and this trial, to date, has generated the most convincing 
Panel 3: REMAP-CAP trial
The Randomised, Embedded, Multifactorial, Adaptive Platform 
Trial for Community-Acquired Pneumonia (REMAP-CAP; 
NCT02735707) is a platform trial evaluating the effects of a 
range of interventions to improve the outcomes of patients 
admitted to the intensive care unit (ICU) with community-
acquired pneumonia.83 The adaptive trial design was planned, 
before the COVID-19 pandemic, for the evaluation of multiple 
treatments in the event of a respiratory pandemic resulting in 
critical illness. REMAP-CAP has since changed its original focus 
of community-acquired pneumonia to COVID-19. The trial spans 
233 active sites with a total of 1195 patients, including 
657 patients with suspected or confirmed COVID-19 (as of 
June 25, 2020). The existing infrastructure and protocol enabled 
REMAP-CAP to efficiently and rapidly adapt in the event of the 
COVID-19 outbreak. The key changes included “modification of 
the primary end-point, so that information is available more 
quickly; description of the statistical model that will be used to 
analyze data for patients with proven or suspected pandemic 
infection; description of changes to statistical thresholds for 
declaring an intervention to be equivalent, superior, or inferior 
to another; and specification of pathways that permit the Data 
Safety Monitoring Board to liaise directly with public health 
authorities if REMAP-CAP produces results that are of relevance 
to public health”.74 The COVID-19 domains of REMAP-CAP 
include the evaluation of long-term macrolide therapy as a 
modulator of immune function, and the evaluation of 
alternative corticosteroid strategies. An additional five domains 
specific to COVID-19 were granted ethical approval. These 
domains are: (1) antiviral therapy (no antiviral therapy for 
COVID-19 [and no placebo], lopinavir–ritonavir, 
hydroxychloroquine, and the combination of 
hydroxychloroquine and lopinavir–ritonavir); (2) immune 
modulation therapy (no immune-modulating therapy for 
COVID-19 [and no placebo], interferon beta, IL-1 receptor 
antagonist [anakinra], tocilizumab, and sarilumab); (3) antibody 
therapy (convalescent plasma); (4) therapeutic anticoagulation 
(low molecular-weight heparin or unfractionated heparin 
compared with standard pharmacological thromboprophylaxis); 
and (5) vitamin C (high-dose vitamin C for patients with severe 
community-acquired pneumonia including pneumonia caused 
by COVID-19). Additional interventions continue to be 
considered for introduction to the trial. Given that REMAP-CAP 
had planned for a respiratory pandemic using an adaptive 
clinical trial design before the COVID-19 pandemic, the already 
existing protocol and the trial’s infrastructure was able to start 
enrolling patients with COVID-19 being admitted to ICUs across 
several countries.
For more on the REMAP-CAP 
trial see https://www.remapcap.
org/
For more on the RECOVERY trial 
see https://www.recoverytrial.
net/
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evidence on the complete absence of clinical efficacy 
of hydroxychloroquine and the clinical efficacy of dexa-
methasone for patients hospitalised with COVID-19.84,85
Capacity and infrastructure building in LMICs 
There has been inadequate geographical representation 
of LMICs in the COVID-19 clinical trials landscape.13,87 
The majority of ongoing COVID-19 clinical trials are 
being done in the EU, the UK, and North America, and 
there are very few trials being done in Africa, south and 
southeast Asia, central America, and South America.13,87 
There is an essential need to expand evaluation of 
affordable and scalable COVID-19 interventions in low-
resource settings, as they are often hit harder by the 
adverse effect of disasters and pandemics of this 
magnitude due to extreme poverty of their population 
and a fragile health-care system.88,89
Since most monetary funding for research in LMICs 
comes from outside the regions, there has almost always 
been a power imbalance between the researchers from 
the sponsoring high-income countries (HICs) and the 
researchers within LMICs.90,91 HIC researchers should not 
just involve LMIC researchers as a means of recruiting 
trial participants; it is important to have a true collaborative 
scientific partnership from the project conception. More 
equitable collaborations between HICs and LMICs can 
have a multitude of benefits for global health research. 
Effective engagement with representatives from the study 
location can be an effective tool to formulate important 
research questions by identifying contextually adapted 
needs and priorities set by the country or countries 
in which the study is based. Effective engagement 
through equitable collaboration can improve contextual 
understanding of the study region so that appropriate 
interventions and trial design strategies are developed, 
leading to meaningful and valid outputs that can be used 
to inform policies, change public health, and benefit 
clinical practice.
Funding decisions about clinical trial research should 
aim to create long-term support for LMICs. Long-term 
human resource utilisation should be viewed as a top 
priority, as it can be an effective measure to address 
common concerns regarding education or training and 
the capacity of the region to undertake high-quality 
clinical trial research.92 Efforts to build capacity for 
clinical trials have been led by organisations such as the 
Cochrane Collaboration and universities in which clinical 
trial capacity building is frequently provided as short 
workshops by visiting investigators.93,94 Unfortunately, in 
global health research, investigators usually only recruit 
staff for the duration of the trial, when resources permit, 
and staff are removed from their jobs after completion 
of the trial. The short-term nature of many clinical 
trials often results in a subsequent loss of intellectual 
and infrastructural capacity when the trial has ended; 
therefore the opportunity to improve local capacity and 
infrastructure is missed. The capacity of regulatory and 
ethical oversight review committees in LMICs should 
also continue to be developed. A major hurdle in rapid 
regulatory and ethical oversight review committees in 
Panel 4: RECOVERY trial
The Randomised Evaluation of COVID-19 Therapy (RECOVERY) 
trial (ISRCTN50189673; NCT04381936) is a large adaptive 
platform trial with a factorial design that is evaluating multiple 
different interventions for hospitalised patients with 
SARS-CoV-2 infection against usual hospital care in the UK. 
As of June 25, 2020, 11 841 patients have been enrolled in the 
RECOVERY trial across 176 hospitals. Rapid recruitment for the 
trial was made possible due to unprecedented leadership and 
national-level collaborations across the UK. The RECOVERY trial, 
to date, has generated the most convincing evidence on the 
clinical efficacy of two different therapies for patients 
hospitalised with COVID-19. On June 5, 2020, the RECOVERY 
trial researchers announced their decision to discontinue their 
evaluation of hydroxychloroquine due to complete absence of 
clinical efficacy.84 When data from 1542 patients were randomly 
assigned to hydroxychloroquine and were compared with 
3132 patients randomly assigned to the control group, 
hydroxychloroquine did not show any clinical benefits on 
28-day mortality (23·5% in the control group vs 25·7% in the 
hydroxychloroquine group; hazard ratio 1·11 [95% CI 
0·98–1·26]). On June 22, 2020, the RECOVERY trial published 
their preliminary findings on low-dose dexamethasone 
(6 mg once daily for 10 days) as a preprint.85 This analysis 
included data from 2104 patients who were randomly assigned 
to the dexamethasone group and 4321 patients randomly 
assigned to the control group. For the overall population, 
dexamethasone had an age-adjusted relative risk (RR) 
of 0·83 (95% CI 0·74–0·92) for 28-day mortality when 
compared with the control group (mortality rate of 21·6% in 
the dexamethasone group vs 24·6% in the control group). 
The mortality reduction benefits varied among patients that 
received different levels of respiratory support at 
randomisation. For instance, dexamethasone did not 
significantly reduce mortality in patients who did not receive 
any ventilation support (RR 1·22, 95% CI 0·93–1·61), but there 
were important mortality reduction benefits from 
dexamethasone for patients who received non-invasive 
ventilation (RR 0·80, 0·70–0·92) and invasive mechanical 
ventilation (RR 0·65, 0·51–0·82). As of Nov 26, 2020, the 
RECOVERY trial is investigating dexamethasone in children 
only, and colchicine, tocilizumab, convalescent plasma therapy, 
REGN-COV2 (casirivimab plus imdevimab), and aspirin in the 
prevention of mortality among inpatients with COVID-19 
within the UK National Health Service hospitals. There might be 
also be new interventions that could be added into this large 
trial network established across the UK.
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LMICs is that the expert reviewers typically have full-time 
employment commitments in academia and volunteer or 
contribute part-time to the review committee. Capacity 
development should therefore extend beyond frameworks 
and systems and include the development of funding 
models to recruit and maintain dedicated expert 
reviewers.
To reach the long-term goal of building sustainable 
capacity for clinical research in LMICs, then it is 
important to move away from funding short-term small-
scale clinical trials. Instead of multiple clinical trials that 
compete against each other, platform trials can create a 
framework in which multiple questions can be addressed 
over time in one large trial that can provide convincing 
and conclusive evidence.8,64 Platform trials can also be 
used to improve capacity and infrastructure in LMICs. 
For instance, funding large-scale long-term platform 
trials can help to ensure long-term involvement of local 
staff, providing opportunities for the staff to develop skills 
and gain experience, ultimately helping to build technical 
and other research skills in the region. The overall process 
of clinical trial research should leave behind a footprint of 
expertise and a sustainable infrastructure. Beyond 
providing access to the inter ventions if they are shown to 
be superior to the standard of care, clinical trial research 
in LMICs should plan post-trial actions that contribute to 
the country’s economy, such as long-term plans for 
human resources and infrastructure.
There is an immense potential to build sustained 
infrastructure in low-resource environments, reduce 
human resource challenges and costs, and more 
efficiently partner with LMIC communities. Perpetual 
clinical trials provide an opportunity to answer multiple 
questions about several interventions in the most 
efficient way imagined, paving a pathway for continuous 
improvement. Building on successful examples of 
perpetual trials, such as the Solidarity trial, REMAP-CAP, 
and the RECOVERY trial, and expansion into low-
resource settings will allow for opportunities to build 
capacity and infrastructure in these countries. We hope 
for an openness by funders to embrace these innovative 
approaches for LMICs, not only for COVID-19 research, 
but also to answer other important clinical research 
questions. This approach would require a considerable 
amount of collaboration between researchers, but it is 
clear that collaborative research practices are important 
to prevent a chaotic, competitive landscape when doing 
clinical trial research in the future.
Conclusions 
There is a need to improve coordination and collaboration 
in clinical trial research for global health. Under the 
current incentive system, clinical research efforts around 
the world will probably continue independently with 
issues that have been highlighted in the previous papers 
of this Series95,96 and in this fourth paper through the 
example of COVID-19. We hope that the COVID-19 
pandemic will become a historical turning point that 
leads to better coordination and collaboration within the 
medical research community, but this outcome will first 
require buy-in from funders and global health researchers 
(particularly those in HICs) who currently control the 
design of trials.
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